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Background: Fatigue is a common yet difficult to treat condition in primary care. The objective of this study is to
evaluate the cost-effectiveness of a brief cognitive behavioral therapy (CBT) based fatigue self-management (FSM)
intervention as compared to usual care among patients with chronic fatigue in primary care.
Methods: An economic evaluation alongside of a parallel randomized controlled study design was used.
Computer-generated variable-sized block randomization plan was used to assign patients into treatment groups and
data collection staff were blinded to group assignments. Patients aged between 18 and 65 years with at least six months
of persistent fatigue and no medical or psychiatric exclusions were enrolled from a large primary care practice in Stony
Brook, New York. The FSM group (n = 37) received two sessions of a nurse-delivered, fatigue self-management protocol
and a self-help book and the usual care group (n = 36) received regular medical care. The effectiveness measure was the
Fatigue Severity Scale and the cost measure was total health care expenditures derived from monthly health services
use diaries during follow-up. A societal perspective was adopted and bootstrapped incremental cost-effectiveness ratios
(ICERs) and net monetary benefit (NMB) were calculated as measures of cost-effectiveness.
Results: The ICER for FSM was -$2358, indicating that FSM dominates UC and it may generate societal cost savings as
compared to usual care. Complete case analysis yielded smaller ICER (−$1199) with greater uncertainties. Net monetary
benefit analysis showed that FSM has a probability of 0.833 (95% CI: 0.819, 0.847) to achieve positive NMB and the
favorable results were not sensitive to assumptions about informal care or treatment costs.
Conclusion: This economic evaluation found initial evidence that a two-session brief CBT-based FSM may be
cost-effective as compared to usual care over 12 months. The FSM intervention is potentially a promising intervention
for chronic fatigue patients in primary care. Additional research is needed to examine the reproducibility and
generalizability of these findings.
Trial registration: ClinicalTrials.gov (NCT00997451, March 28, 2009).
Keywords: Cognitive behavioral therapy, Cost-effectiveness, FatigueBackground
Chronic fatigue is characterized by persistent and recur-
ring fatigue that cannot be alleviated by rest [1,2]. It has
been associated with lower quality of life [3-5] and higher
health care utilization [6-10]. The cost of lost productivity
associated with chronic fatigue has been estimated to be
between £75-£129 million annually in the U.K. and the* Correspondence: meng@usf.edu
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access specialist services [11].
Cognitive behavioral therapy (CBT) has been shown to
be effective in reducing fatigue symptoms as compared
to adaptive pacing therapy or usual care [12], while
graded exercise therapy (GET) has seen mixed results
[13-16]. CBT combines elements of both behavioral ther-
apy and cognitive therapy to facilitate the identification
and reduction of negative thoughts and to build activity
tolerance and positive coping skills among chronic fatigue
patients. However, economic evaluations for the treatmenttd. This is an Open Access article distributed under the terms of the Creative
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and the findings are generally inconclusive [17-20]. In
addition, no economic evaluation study has been re-
ported in the US. The assessment of the relative value of
CBT will be important for programmatic and policy deci-
sions that must balance costs and outcomes of care [21,22].
The purpose of the present study is to compare the
cost-effectiveness of a brief CBT-based Fatigue Self-
Management (FSM) intervention and usual care (UC)
conditions in a sample of primary care patients with
chronic fatigue.
Methods
Chronic fatigue self-management study
The Chronic Fatigue Self-Management Study is a ran-
domized controlled trial involving 111 primary care pa-
tients with chronic fatigue in New York between 2009
and 2011. Details of the study and results of the primary
end point were reported elsewhere [23]. While the study
was powered for the primary outcome of fatigue impact
on functioning, the economic evaluation was designed
as a pilot and feasibility study. All patients were re-
cruited from a family medicine/primary care practice
with 14 attending physicians and 21 family practice resi-
dents. The inclusion criteria for participants were (a) be-
tween 18 and 65 years of age; (b) at least six months of
persistent fatigue with no medical or psychiatric exclu-
sions (as determined by primary care physicians and a
psychiatric nurse). Exclusion criteria were: (a) Medical:
fatigue due to identifiable medical conditions (such as
autoimmune diseases) or to medications (such as beta
blockers); (b) Psychiatric: psychosis or dementia, alcohol
or substance abuse, depression with melancholic or
psychotic features, and anorexia nervosa or bulimia ner-
vosa. These Axis I psychiatric diagnoses were identified
from a nurse-conducted Structured Clinical Interview for
DSM-IV (SCID) [24]. The study protocol received ethical
approval from the Stony Brook University Institutional
Review Board (IRB) and the drafting of this manuscript
adheres to the CONSORT statement [25].
After written informed consent forms and baseline
assessments were obtained, patients were randomly assigned
to one of three groups as follows: CBT-based FSM (n = 37),
attention control (AC) (n = 38), and usual care (UC)
(n = 36). A variable-sized block randomization proced-
ure was used to minimize potential selection bias. The
study statistician generated the random allocation se-
quence, the principal investigator conducted the initial
telephone interview, and a graduate student assigned
participants to interventions. Data collection staff were
blinded to the group assignment and sample size was
chosen to ensure adequate power to detect treatment
effect on the primary outcome. Additional details of the
study have been reported elsewhere [23]. The CBT-basedFSM group received two individual face-to-face fatigue
self-management training sessions with a nurse (for up to
60 minutes) and a 61-page self-management booklet
containing material assigned and discussed in the two
sessions. This protocol was adapted from an efficacious
12-session CBT program for Chronic Fatigue Syndrome
(CFS) [26]. Patients in the AC group received two sessions
with a nurse therapist regarding emotional support and
home-based self-monitoring of symptoms, affect, and
stress. The AC group was designed to control for therapist
attention and homework assignments so that potential
placebo effects can be isolated from the FSM treatment ef-
fect. The UC group received no treatment beyond usual
medical care. All three groups were assessed at baseline
and 12-month follow-up [23]. For the purpose of this
study, patients in the AC group were excluded because
the attention control would be dominated by the control
group as it requires higher costs (due to therapists’ atten-
tion) with no commensurate benefit.
Outcome measures
The primary outcome was the Fatigue Severity Scale
(FSS). The FSS was designed to measure the effect of fa-
tigue on functioning. It is comprised of nine items rated
on a 7-point Likert scale, where one indicates no impair-
ment and seven indicates severe impairment. A one-point
decrease on the FSS is considered clinically significant im-
provement. It is a validated scale for use in CFS with high
internal consistency [27] and has been shown to be sensi-
tive to treatment change [28].
Service use and costs
Health resource use and costs were identified and valued
from the societal perspective for the Reference Case ana-
lysis following the “Panel Recommendations” [29]. Health
care resource use was measured with a modified version
of the Client Service Receipt Inventory (CSRI), a validated
health care utilization diary [30], to record health service
use as well as informal care for the 3 month period prior
to baseline and on a monthly basis by trained staff via a
telephone interview during the post-treatment follow-up
period.
To evaluate the economic effects of the prescribed
treatments, we identified relevant cost categories of re-
source use by measuring utilization in each resource cat-
egory (direct and indirect) and identifying the unit costs
(prices) of the corresponding category. As economic
endpoints, direct health care costs, direct non-health
care costs and indirect costs were included [31]. The dir-
ect study-based health care costs included costs of the
behavioral interventions and the economic consequences
of the programs in terms of health services utilization
before and after the intervention (direct health care costs).
Intervention costs include costs of personnel (clinical
Table 1 Unit prices used to value the different types of
services in the analysis (in 2010 $)
Service Unit Unit cost ($)
Primary care physician visit 116
Nurse practitioner visit 87
Specialist visit 147
Physical/Occupational therapist visit 87
Social worker visit 73
Homeopath/Acupuncturist visit 59
Dentist visit 147
Emergency room visit 638
Hospital visit 1916





Blood test count 34
Child/personal care hour 10
Hourly wage hour 21
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material (self-help booklet), time spent by study personnel
and patients (intervention sessions and travel), facility
costs (space, maintenance, and utilities), and other costs
(advertising and telephone services). Costs were allo-
cated to individual patients based on the number of
sessions they attended. Direct health care costs in-
cluded the costs of hospitalizations and visits to health
care providers (e.g. general practitioner, specialist, physical
therapist, alternative medicine providers) and the use of
prescription and over-the-counter medications. The direct
non-health care costs include out-of-pocket expenses,
costs of paid and unpaid help, and travel costs of attend-
ing medical appointments. As part of the modified CSRI,
information on the frequency of paid help, travel time for
medical appointments, and the number of illness-related
absences from paid or unpaid work were collected. Indir-
ect costs include the value of production lost to society
due to illness-related absence from work (paid or unpaid).
For each category of health care resources, we used
standard approaches to estimate costs [32,33]. Unit costs
for major health care services (e.g. provider office visits)
and prescription medications were based on national
average of Medicare payment rates, estimated from the
2010 Medical Expenditure Panel Survey (MEPS). Medi-
care payment rates are widely used as approximate mea-
sures of the opportunity costs associated with health
services use in economic evaluations. Unit costs of vari-
ous diagnostic tests were based on 2010 Medicare Phys-
ician Fee Schedule Payment Schedule published by the
Centers for Medicare and Medicaid Services (Table 1).
Although informal caregivers are not paid for their in-
puts, there is still a cost involved from the societal perspec-
tive when other opportunities are forgone. It is assumed
that the work provided by informal caregivers will be simi-
lar to that of home care workers. Therefore, we used the
national average hourly wage of home health and personal
care aides from the 2010 Occupational Employment and
Wage Estimates produced by the Bureau of Labor Statistics
(BLS) to approximate the unit cost of informal caregivers
as well as unpaid help by family and friends.
The days of lost work were valued using average
wages obtained from the U.S. Census Bureau (U.S.
Census Bureau, Statistical Abstract of the United States,
2012). We calculated daily wages from annual wages and
then estimated the total lost income for each patient as a
product of the total number of days missed work and daily
wages. For participants who did not work, we used ½ wage
rates as estimates of lost productivity [29]. Because the
treatment phase for all patients began in 2009 and ended
in 2011, we used 2010 prices and did not adjust for infla-
tion [32]. For each patient, total health care expenditures
were calculated as the sum of the volume of various ser-
vices multiplied by the corresponding unit costs.Analysis
Outcomes
Statistical analyses were performed using STATA (Version
11, College Station, TX). We first compared patients’
baseline characteristics in the FSM and UC groups using
appropriate tests of statistical significance (i.e. Chi-square
test for binary variables, t-test for continuous variables).
Last observation carried forward (LOCF) method was used
to impute the 12-month outcome data for 26 individuals
who did not complete the 12-month assessment and no
cost data was imputed. For the effectiveness measure,
we used the difference-in-difference approach in multi-
variate regression analysis to identify the effects of the
intervention by controlling for baseline effectiveness or
cost measures, as well as baseline patient characteris-
tics (age, gender, education, marital status, employ-
ment status, number of chronic conditions, and
number of symptoms).
For the cost measure, our primary interest was to
examine the between-group differences in total health
care expenditures among participants in the FSM as
compared to those in the UC group. Therefore, we esti-
mated total expenditures using a generalized linear model
(GLM) with a gamma distribution and log link function to
account for the distributional characteristics of expend-
iture data. We chose GLM over ordinary least squares
models (with log-transformed dependent variables) based
on the modified Park Test examining the distributional
characteristics of residuals from both approaches as sug-
gested by Manning and Mullahy [22,34].
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ICERs were estimated using the standard formula:
ICER = (ΔC1 −ΔC2)/(ΔE1 − ΔE2), where ΔC1 − ΔC2 is the
difference in the average cost change from baseline to 1-
year follow-up between two groups and (ΔE1 − ΔE2) is the
difference in the average effectiveness change between the
two groups [35]. We plotted a cost-effectiveness plane
(with a cost dimension and a FSS dimension) to show the
incremental change in FSS scores and in costs for FSM
versus UC. The plane is divided into four quadrants:
northeast (more effective, more costly), northwest (less ef-
fective, more costly), southwest (less effective, less costly),
and southeast (more effective, less costly). To account for
uncertainty involved in the statistical inference, 3000 in-
cremental cost-effectiveness values were obtained through
bootstrapping, a non-parametric method of statistical in-
ference in which the empirical sampling distribution is
estimated by repeated re-sampling from the observed
distribution [36]. To evaluate the potential impact of
imputation on ICER, plots from both the imputed
sample and the complete case analysis were generated.
Because negative ICER may result in ambiguity as to
which group is dominated, we used the net-benefit ap-
proach to evaluate the cost-effectiveness of the treatment
group as suggested in the literature [37-40]. The net bene-
fit approach can be defined as: NMB = RTΔE − ΔC,
where NMB = Net Monetary Benefit, RT =Threshold
of Willingness-to-pay per unit of benefit, ΔE =differ-
ence in effectiveness (net reduction in FSS score), and
ΔC =difference in cost. Given a certain level of willingness-
to-pay (often unknown from the societal perspective),
NMB measures the net benefit the decision-maker is will-
ing to pay per unit of increased effectiveness (RT), less the
increase in cost (ΔC). As a result, a program is deemed
cost-effective if NMB > 0 [32]. In the present study, net
benefits were calculated for each patient in the sample
using a range of values ($0 to $10000 in $50 increments)
for RT to reflect the uncertainty regarding the societal
willingness-to-pay per unit of effectiveness. We then com-
pared differences in net benefits between FSM and UC
using bootstrapped multiple regression models controlling
for patient characteristics and pre-treatment FSS and costs.
Sensitivity analysis
To test the robustness of the results, we conducted sen-
sitivity analyses under two conservative scenarios. First,
because the cost of informal care is likely to be excluded
from the total cost in the employer’s decision-making
process of whether to adopt the intervention, we calcu-
lated the alternative total costs by assuming that the unit
cost of informal care equals to zero. Second, as there is
some uncertainty regarding the cost of the FSM inter-
vention, we also calculated total costs assuming the
intervention costs are 100 percent higher than ourestimates. Results from this analysis will show whether




Although 75 individuals were randomized into the FSM
(n = 37) and UC (n = 36) groups, the complete-case
cost-effectiveness analysis excluded 26 individuals due to
missing both effectiveness and costs data (Figure 1). Pa-
tients in FSM and UC groups did not differ significantly
in baseline patient characteristics, nor are those in-
cluded in the cost-effectiveness analysis differ signifi-
cantly from those excluded (data not shown).
Table 2 presents average use of services and average
costs by resource use categories for both groups during
the study period. Overall, the FSM group had lower un-
adjusted average annual total cost as compared to the
UC group before intervention ($3026 vs. $4862) and
after the intervention ($4039 vs. $6903). As a result, the
FSM group had smaller increase in average annual total
costs over the study period ($1012 vs. $2041) even after
the intervention costs were factored in. In terms of
effectiveness, the FSM group had bigger reduction in
FSS score as compared to the UC group (0.99 vs. 0.26).
It appears that patients in the FSM group had smaller
increases in provider visits, larger decreases in ER/
hospital visits and absence from work. In summary, the
unadjusted analysis showed that on average, the FSM group
had better outcome and smaller increase in costs as
compared to the UC group.
Table 3 summarizes the regression-adjusted incremen-
tal cost, incremental effectiveness, and incremental cost-
effectiveness ratios (ICERs) for FSM versus UC. The
FSM appeared to be more effective in improving FSS
score and was associated with somewhat lower total
costs as compared to UC. Over the 12 months study
period, the FSM group had an ICER of −2358 (FSM
dominant). This means that compared to UC, FSM inter-
vention generated a societal saving of $2358 for each point
reduction in the FSS score. When the bootstrapped 95%
confidence interval for the ICER is considered, results
suggest that the favorable ICER results for FSM should be
interpreted as preliminary evidence because zero was
included in the confidence interval. The same analysis
using only the complete cases yielded similar results
with somewhat smaller savings with wider confidence
intervals, as expected from a smaller sample.
Figure 2 shows the incremental cost-effectiveness for
FSM and AC as compared to UC in 3000 bootstrapped
samples. Consistent with results from bivariate analysis
presented in Table 2, the great majority of the ICER for
FSM vs. UC fell in the southeast quadrant of the ICER
plane, indicating than FSM is likely to be more effective




Due to exclusion criteria (n=102)
Declined to participate (n=76)




Lost to follow-up (n=12)




Lost to follow-up (n=13)




Lost to follow-up (n=16)
7 had missing outcome 
and cost data






19 with complete data





because AC is dominated 
by UC due to higher 




18 with complete data
15 with imputed effectiveness 
data
Figure 1 CONSORT flow diagram.
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using complete cases yielded similar results with greater
uncertainty.
Figure 3 presents the cost-effectiveness acceptability
curve for FSM as compared to UC, as well as acceptabil-
ity curves under the two scenarios of the sensitivity ana-
lysis. Scenario 1 assumes that the unit cost of informalcare equals to zero and scenario 2 assumes that the
intervention costs are 100 percent higher than the costs
calculated in the study. For the base case, even if society
values each point reduction in FSS score at $0, the prob-
ability that the FSM would generate a positive NMB is
0.833 (95% CI: 0.819, 0.847). Reducing the value of infor-
mal care had virtually no impact on NMB and doubling
Table 2 Costs and changes in costs for UC and FSM, by category and period
Pre (3 months) Post (12 months)
Variables n (%) users # of Contacts ± SD† Cost ($)† n (%) users # of Contacts ± SD† Cost ($)† Changes
in Costs ($)
Usual Care (UC), n = 33
1. GP visit 21 (64) 1 ± .3 70 21 (76) 0 ± .2 47 −23
2. Specialist visit 15 (45) 1 ± .5 26 15 (67) 1 ± 1.5 60 34
3. Other provider visit 11 (33) 1 ± 1.1 58 11 (67) 1 ± 1.6 93 35
4. Provider (1 + 2 + 3) 26 (79) 1 ± 1.2 97 26 (85) 3 ± 2.4 162 65
5. ER/hospital visit 2 (6) 1 ± .2 319 2 (24) 0 ± .2 260 −59
6. Rx medications 26 (79) 1 ± .6 32 26 (85) 1 ± .8 29 −3
7. Laboratory test 21 (64) 1 ± .5 44 21 (79) 1 ± .9 47 3
8. Informal care, hours 16 (48) 43 ± 38.3 427 16 (79) 33 ± 32.3 334 −93
9. Missed work, hours 13 (39) 8 ± 8.1 125 13 (55) 6 ± 4.5 91 −34
10. Total cost (4 + 5 + 6 + 7 + 8 + 9)* 1216 1726
11. Annualized average cost 4862 6903 2041
12. Intervention cost 0 0
13. Grand total (11 + 12) 4862 6903 2041
Fatigue Self-Management (FSM),
n = 30
1. GP visit 15 (50) 1 ± .4 70 15 (73) 0 ± .7 49 −21
2. Specialist visit 8 (27) 1 ± 1.7 37 8 (80) 1 ± .8 43 6
3. Other provider visit 8 (27) 1 ± .8 77 8 (63) 1 ± 1.8 83 6
4. Provider (1 + 2 + 3) 21 (70) 1 ± 1.3 93 21 (97) 2 ± 2 127 34
5. ER/hospital visit 3 (10) 0 ± 0 213 3 (20) 0 ± .1 102 −111
6. Rx medications 21 (70) 1 ± .6 30 21 (87) 1 ± .5 21 −9
7. Laboratory test 14 (47) 1 ± .4 38 14 (77) 1 ± 1.1 29 −9
8. Informal care, hours 8 (27) 27 ± 29.5 269 8 (40) 22 ± 29.5 220 −49
9. Missed work, hours 10 (33) 10 ± 7.5 166 10 (50) 5 ± 4.7 83 −83
10. Total cost (4 + 5 + 6 + 7 + 8 + 9)* 757 939
11. Annualized average cost 3026 3754 728
12. Intervention cost‡ 0 285
13. Grand total (11 + 12) 3026 4039 1012
GP = General Practitioner; ER = Emergency Room; Rx = Prescription; †contacts/costs were calculated among users; *Total costs during the post- period were
standardized to 3-months so that the results are comparable to the pre- period.
‡Intervention costs included: Personnel ($69), booklet ($10), time spent ($154), and facility and other ($52).
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tive NMB to 0.735 (95% CI: 0.710, 0.760) assuming $0
willingness-to-pay.
Discussion
While CBT has an effect on fatigue symptoms compar-
able to graded exercise therapy and counseling in pri-
mary care, the longer term cost-effectiveness of CBT
remains unclear [17-20]. This analysis tested the cost-
effectiveness of a brief two-session CBT intervention
with a self-management education component in a pilot
study of primary care patients with chronic fatigue. Toour knowledge, this study appears to be the first eco-
nomic evaluation conducted alongside of a randomized
controlled trial to examine the cost-effectiveness of a
brief CBT-based FSM intervention in the U.S. The ana-
lysis of the outcome results at 12-month showed signifi-
cant differences between the FSM group and the UC
group after adjusting for baseline characteristics. The
FSM intervention appears to be cost-effective in that it
was associated with reduced fatigue impact on function-
ing and lower total costs.
Previous studies have shown that CBT interventions
conducted in primary care by trained professionals were
Table 3 Adjusted incremental costs, effectiveness, and cost-effectiveness ratios
Intervention Incremental cost (95% CI) Incremental effectiveness (95% CI) ICER
Imputed effectiveness data, 12 mo
UC Reference Reference Reference
FSM -$1729 (−5125,1095) 0.73 (0.15, 1.42) FSM dominant
Complete cases, 12 mo
UC Reference Reference Reference
FSM -$1464 (−6670,3350) 1.22 (0.16,2.55) FSM dominant
UC = Usual Care; FSM = Fatigue Self-Management; CI = Confidence Interval.
ICER = Incremental Cost-Effectiveness Ratio, in 2010 US dollars; ICER = −2358 for imputed data, and −1199 for complete cases. Because the magnitude of negative
ICER do not convey the same information as positive ICER do, “FSM dominant” is reported to indicate that FSM is more effective at lower costs as compared
to UC.
Effectiveness and costs were obtained from multivariate regression models adjusting for the following baseline characteristics: age gender, education, marital
status, employment status, number of chronic conditions, and number of symptoms.
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group CBT was not [15]. This study provides the first U.S.
economic evidence that a brief FSM intervention may
offer a promising alternative to traditional multi-session
CBT delivered by experienced therapists, as it only in-
volves two individual training sessions plus a self-help
booklet, as compared to 6–16 visits in CBT trials for CFS
patients [9]. This is consistent with the finding from a re-
cent study of non-traditional face-to-face CBT, which
showed that an internet-based CBT was cost-effective for
severe health anxiety at 1-year follow-up [41].
A number of limitations should be considered in inter-
preting the findings. First, the attrition rate of this pilot
study was high, suggesting that the compliance for the
FSM intervention is not optimal or that the burden of
monthly follow-up may be high, or both. As a result,
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Figure 2 Plots of incremental cost-effectiveness ratios for fatigue self
Note: Four quadrants: northeast (more effective, more costly), northwest (le
southeast (more effective, less costly). Imputed sample included 26 individuthe FSM group may due to chance. Future studies of
CBT interventions should focus on better data collection
techniques such as a dedicated staff person for follow-up
and implementing oversight processes to reduce the
amount of missing data [42]. However, given the self-
management nature of this intervention, it mimics adop-
tion rates for other behavioral interventions (such as diet
and exercise) in real world settings. In addition, to the
extent that the rates of attrition were similar across all
three groups and that no statistical differences were de-
tected between completers and non-completers, the at-
trition is unlikely to bias our findings. Nevertheless,
future studies should examine what factors contribute to
attrition and explore whether attrition can be reduced
by modifying the intervention protocols. A second limi-
tation is the imputation method used, which is based on
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Figure 3 Cost-effectiveness acceptability curve comparing fatigue self-management versus usual care, base case and sensitivity
analysis. Note: Scenario 1: informal help was valued at $0; Scenario 2: intervention cost was valued at 2 times of the base case rate.
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may not be the case. However, the complete case ana-
lysis suggests that the findings were not driven by the
imputation method used. Third, because patients were
recruited from one geographic location, findings may
not be generalizable to patients in other locations. A
multi-center randomized controlled study is needed to
test whether the FSM intervention is cost-effective in
more diverse chronic fatigue patient populations. Finally,
it is unclear to what extent the beneficial treatment ef-
fect for fatigue impact on functioning lasts beyond the
1-year follow-up period.
Despite these limitations, the present study provides im-
portant initial evidence of cost-effectiveness for a new
brief two-session CBT-based FSM intervention in primary
care. It has the strength of incorporating the economic
data collection into the clinical outcomes measures by
design and as a result, both cost and effectiveness data
were collected from the same individuals [43]. Never-
theless, additional research is needed to examine how
to improve treatment compliance and whether similar
cost-effectiveness can be achieved in a broader patient
population across multiple primary care practices and/
or regions.
Conclusion
The brief two-session CBT-based fatigue self-management
intervention appeared to be cost-effective in this pilot study
in that the intervention costs was more than offset by cost
savings generated from reduced health services utilization
during the 1 year follow-up. However, due to the small
sample size and high attrition rates, interpretation of thefindings should be cautious. Nevertheless, less labor-
intensive modalities of CBT such as the brief nurse-led
self-management approach reported here should be
tested in future studies in primary care.
Abbreviations
UC: Usual care; FSM: Fatigue self-management; CI: Confidence interval;
FSS: Fatigue severity scale; ICER: Incremental cost-effectiveness ratio;
NMB: Net monetary benefit.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HM performed the data analysis, participated in the research design, and
revised the manuscript. FF originated the idea of the study, developed the
research proposal and led the study. FF supervised the overall study, data
collection, reviewed the analysis, and participated in the interpretation of the
data and preparation of the manuscript. MCB participated in the
interpretation of the data and preparation of the manuscript. All authors
have read and approved the final manuscript.
Acknowledgements
Conflict of Interest and Source of Funding:
The study was supported by NIH grant R01NR010229 (National Institute of
Nursing Research).
Author details
1School of Aging Studies, University of South Florida, 13301 Bruce B Downs
Blvd., MHC 1300, Tampa, FL 33620, USA. 2Department of Psychiatry, Stony
Brook University Medical Center, Department of Psychiatry and Behavioral
Science, Putnam Hall/South Campus, Stony Brook, NY 11794, USA.
Received: 21 May 2014 Accepted: 24 October 2014
References
1. Whiting P, Bagnall AM, Sowden AJ, Cornell JE, Mulrow CD, Ramirez G:
Interventions for the treatment and management of chronic fatigue
syndrome: a systematic review. JAMA 2001, 286(11):1360–1368.
Meng et al. BMC Family Practice 2014, 15:184 Page 9 of 9
http://www.biomedcentral.com/1471-2296/15/1842. Burns D: Chronic fatigue syndrome or myalgic encephalomyelitis. Nurs
Stand 2012, 26(25):48–56.
3. Chalder T, Deale A, Wessely S: The Treatment of Chronic Fatigue
Syndrome. In Difficult Clinical Problems in Psychiatry. edn. Edited by Rader M,
Naber D. London: Martin Dunitz; 1999:135–153.
4. Kroenke K, Wood DR, Mangelsdorff AD, Meier NJ, Powell JB: Chronic fatigue
in primary care. Prevalence, patient characteristics, and outcome.
JAMA 1988, 260(7):929–934.
5. Assefi NP, Coy TV, Uslan D, Smith WR, Buchwald D: Financial, occupational,
and personal consequences of disability in patients with chronic fatigue
syndrome and fibromyalgia compared to other fatiguing conditions.
J Rheumatol 2003, 30(4):804–808.
6. Friedberg F: Chronic fatigue syndrome, fibromyalgia, and related
illnesses: a clinical model of assessment and intervention. J Clin Psychol
2010, 66(6):641–665.
7. Jason LA, Taylor RR, Kennedy CL, Song S, Johnson D, Torres S: Chronic
fatigue syndrome: occupation, medical utilization, and subtypes in a
community-based sample. J Nerv Ment Dis 2000, 188(9):568–576.
8. McCrone P, Darbishire L, Ridsdale L, Seed P: The economic cost of chronic
fatigue and chronic fatigue syndrome in UK primary care. Psychol Med
2003, 33(2):253–261.
9. Price JR, Mitchell E, Tidy E, Hunot V: Cognitive behaviour therapy for
chronic fatigue syndrome in adults. Cochrane Database Syst Rev 2008,
3, CD001027.
10. Wearden AJ, Dowrick C, Chew-Graham C, Bentall RP, Morriss RK, Peters S,
Riste L, Richardson G, Lovell K, Dunn G: Nurse led, home based self help
treatment for patients in primary care with chronic fatigue syndrome:
randomised controlled trial. BMJ 2010, 340:c1777.
11. Collin SM, Crawley E, May MT, Sterne JA, Hollingworth W: The impact of
CFS/ME on employment and productivity in the UK: a cross-sectional
study based on the CFS/ME national outcomes database. BMC Health
Serv Res 2011, 11:217.
12. White PD, Goldsmith KA, Johnson AL, Potts L, Walwyn R, DeCesare JC, Baber HL,
Burgess M, Clark LV, Cox DL, Bavinton J, Angus BJ, Murphy G, Murphy M,
O'Dowd H, Wilks D, McCrone P, Chalder T, Sharpe M: Comparison of adaptive
pacing therapy, cognitive behaviour therapy, graded exercise therapy, and
specialist medical care for chronic fatigue syndrome (PACE): a randomised
trial. Lancet 2011, 377(9768):823–836.
13. Moss-Morris R, Sharon C, Tobin R, Baldi JC: A randomized controlled
graded exercise trial for chronic fatigue syndrome: outcomes and
mechanisms of change. J Health Psychol 2005, 10(2):245–259.
14. Chambers D, Bagnall AM, Hempel S, Forbes C: Interventions for the
treatment, management and rehabilitation of patients with chronic
fatigue syndrome/myalgic encephalomyelitis: an updated systematic
review. J R Soc Med 2006, 99(10):506–520.
15. O’Dowd H, Gladwell P, Rogers CA, Hollinghurst S, Gregory A: Cognitive
behavioural therapy in chronic fatigue syndrome: a randomised
controlled trial of an outpatient group programme. Health Technol Assess
2006, 10(37):iii–iv. ix-x, 1–121.
16. Twisk FN, Maes M: A review on cognitive behavorial therapy (CBT) and
graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic
fatigue syndrome (CFS): CBT/GET is not only ineffective and not
evidence-based, but also potentially harmful for many patients with
ME/CFS. Neuro Endocrinol Lett 2009, 30(3):284–299.
17. Chisholm D, Godfrey E, Ridsdale L, Chalder T, King M, Seed P, Wallace P,
Wessely S: Chronic fatigue in general practice: economic evaluation of
counselling versus cognitive behaviour therapy. Br J Gen Pract 2001,
51(462):15–18.
18. McCrone P, Ridsdale L, Darbishire L, Seed P: Cost-effectiveness of cognitive
behavioural therapy, graded exercise and usual care for patients with
chronic fatigue in primary care. Psychol Med 2004, 34(6):991–999.
19. Severens JL, Prins JB, van der Wilt GJ, van der Meer JW, Bleijenberg G:
Cost-effectiveness of cognitive behaviour therapy for patients with
chronic fatigue syndrome. QJM 2004, 97(3):153–161.
20. Sabes-Figuera R, McCrone P, Hurley M, King M, Donaldson AN, Ridsdale L:
Cost-effectiveness of counselling, graded-exercise and usual care for
chronic fatigue: evidence from a randomised trial in primary care.
BMC Health Serv Res 2012, 12:264.
21. Yates BT: Toward the incorporation of costs, cost-effectiveness analysis,
and cost-benefit analysis into clinical research. J Consult Clin Psychol 1994,
62(4):729–736.22. Doshi JA, Glick HA, Polsky D: Analyses of cost data in economic evaluations
conducted alongside randomized controlled trials. Value Health 2006,
9(5):334–340.
23. Friedberg F, Napoli A, Coronel J, Adaomwicz J, Seva V, Caikauskaite I, Ngan M,
Chang J, Meng H: Chronic fatigue self management in primary care: a
randomized trial. Psychosom Med 2013, 75:650–657.
24. First MB, Spitzer R, Gibbon M, Willams J: Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I). New York, NY: New York State Psychiatric
Institute; 2001.
25. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: updated
guidelines for reporting parallel group randomized trials. Ann Intern Med
2010, 152(11):726–732.
26. Jason L, Torres-Harding S, Friedberg F, Corradi K, Njoku M, Donalek J, Reynolds N,
Brown M, Weitner B, Rademaker A, Papernik M: Non-pharmacologic
interventions for CFS: a randomized trial. J Clin Psychol Med Settings
2007, 14(4):275–296.
27. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD: The fatigue severity
scale. Application to patients with multiple sclerosis and systemic lupus
erythematosus. Arch Neurol 1989, 46(10):1121–1123.
28. Taylor RR, Jason LA, Torres A: Fatigue rating scales: an empirical
comparison. Psychol Med 2000, 30(4):849–856.
29. Gold M, Siegel J, Russell L, Weinstein M: Cost-Effectiveness in Health and
Medicine. New York, New York: Oxford University Press; 1996.
30. Beecham J, Knapp M: Costing Psychiatric Interventions. In Measuring
Mental Health Needs. 2nd edition. Edited by Thornicroft G. ; 2001:200–224.
31. Goossens MEJB, Rutten-Van Mölken MPMH, Kole-Snijders AMJ, Vlaeyen JWS,
Van Breukelen G, Leidl R: Health economic assessment of behavioural
rehabilitation in chronic low back pain: a randomised clinical trial.
Health Econ 1998, 7(1):39–51.
32. Glick HA, Doshi JA, Sonnad SS, Polsky D: Economic Evaluation in Clinical
Trials. New York: Oxford University Press; 2007.
33. Oostenbrink JB, Koopmanschap MA, Rutten FF: Standardisation of costs:
the Dutch Manual for Costing in economic evaluations.
PharmacoEconomics 2002, 20(7):443–454.
34. Manning WG, Mullahy J: Estimating log models: to transform or not to
transform? J Health Econ 2001, 20(4):461–494.
35. Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G: Methods for
the Economic Evaluation of Health Care Programmes. 3rd edition. New York,
NY: Oxford University Press; 2005.
36. Mooney CZ: Bootstrap statistical inference: examples and evaluations for
political science. Am J Polit Sci 1996, 40(2):570–602.
37. Briggs AH, O’Brien BJ, Blackhouse G: Thinking outside the box: recent advances
in the analysis and presentation of uncertainty in cost-effectiveness studies.
Annu Rev Public Health 2002, 23:377–401.
38. Stinnett AA, Mullahy J: The negative side of cost-effectiveness analysis.
JAMA 1997, 277(24):1931–1932.
39. Briggs AH: A Bayesian approach to stochastic cost-effectiveness analysis.
An illustration and application to blood pressure control in type 2
diabetes. Int J Technol Assess Health Care 2001, 17(1):69–82.
40. Richardson G, Epstein D, Chew-Graham C, Dowrick C, Bentall RP, Morriss RK,
Peters S, Riste L, Lovell K, Dunn G, Wearden AJ, FINE Trial Writing group on behalf
of the FINE Trial group: Cost-effectiveness of supported self-management for
CFS/ME patients in primary care. BMC Fam Pract 2013, 14:12.
41. Hedman E, Andersson E, Lindefors N, Andersson G, Ruck C, Ljotsson B:
Cost-effectiveness and long-term effectiveness of internet-based
cognitive behaviour therapy for severe health anxiety. Psychol Med
2013, 43(2):363–374.
42. Fleming TR: Addressing missing data in clinical trials. Ann Intern Med 2011,
154(2):113–117.
43. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, Cook J, Glick H,
Liljas B, Petitti D, Reed S: Good research practices for cost-effectiveness
analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
Value Health 2005, 8(5):521–533.
doi:10.1186/s12875-014-0184-7
Cite this article as: Meng et al.: Cost-effectiveness of chronic fatigue
self-management versus usual care: a pilot randomized controlled
trial. BMC Family Practice 2014 15:184.
